TY - JOUR
T1 - Subcutaneous ivermectin for the treatment of the hyperinfection syndrome by Strongyloides stercoralis
AU - Hennessey, Diana Carolina
AU - Ballesteros, Oscar Andrés
AU - Merchán, Diego Javier
AU - Guevara, Freddy Orlando
AU - Severiche-Bueno, Diego Fernando
N1 - Publisher Copyright:
© 2020, Biomédica. All Rights Reserved
PY - 2020
Y1 - 2020
N2 - Strongyloidiasis is a disease caused by the nematode Strongyloides stercoralis that is endemic in rural regions in tropical and subtropical countries. Immunosuppressed patients have an increased risk of infection by this parasite and are at risk of developing a hyperinfection syndrome which involves a higher risk of death. The syndrome is treated with ivermectin, however, there is no parenteral presentation of this medication for human use in Colombia or the world, which is an important problem in patients who have compromised enteral absorption, for instance, those with intestinal obstructions. We present a case of hyperinfection syndrome by Strongyloides stercoralis in Colombia, which was treated with subcutaneous ivermectin. Our purpose is to encourage pharmacokinetic and pharmacodynamic studies to establish this route of administration in the future as an alternative for those patients who have a high risk of therapeutic failure with the oral route.
AB - Strongyloidiasis is a disease caused by the nematode Strongyloides stercoralis that is endemic in rural regions in tropical and subtropical countries. Immunosuppressed patients have an increased risk of infection by this parasite and are at risk of developing a hyperinfection syndrome which involves a higher risk of death. The syndrome is treated with ivermectin, however, there is no parenteral presentation of this medication for human use in Colombia or the world, which is an important problem in patients who have compromised enteral absorption, for instance, those with intestinal obstructions. We present a case of hyperinfection syndrome by Strongyloides stercoralis in Colombia, which was treated with subcutaneous ivermectin. Our purpose is to encourage pharmacokinetic and pharmacodynamic studies to establish this route of administration in the future as an alternative for those patients who have a high risk of therapeutic failure with the oral route.
UR - http://www.scopus.com/inward/record.url?scp=85102069632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102069632&partnerID=8YFLogxK
U2 - 10.7705/biomedica.5140
DO - 10.7705/biomedica.5140
M3 - Research Article
C2 - 32673452
AN - SCOPUS:85102069632
SN - 0120-4157
VL - 40
SP - 228
EP - 232
JO - Biomedica
JF - Biomedica
IS - 2
ER -